Agios (AGIO) CMO exercises 200 options at $25.01, sells 200

Agios Pharmaceuticals (AGIO) reported an insider transaction by its Chief Medical Officer, Sarah Gheuens.

Rhea-AI Filing Summary

Agios Pharmaceuticals (AGIO) reported an insider transaction by its Chief Medical Officer, Sarah Gheuens. On 10/30/2025, she exercised 200 stock options at $25.01 per share and sold 200 shares at $43.81 pursuant to a Rule 10b5-1 trading plan. Following these trades, she held 61,727 shares of common stock directly.

The derivative table shows 28,584 stock options beneficially owned after the transaction, with an exercise price of $25.01 and an expiration date of 03/01/2033. The option was originally granted on 03/01/2023 for 44,000 shares, vesting 25% on 03/01/2024 with the remainder vesting in 36 equal monthly installments thereafter.

Insider Trade Summary

Exercise and Sale: 200 shares ($4K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Gheuens Sarah

Role Chief Medical Officer

Sold 200 shs ($9K)

Approx. gross sale proceeds $9K

Approx. exercise cost $5K

Approx. pre-tax spread $4K

Type	Security	Shares	Price	Value
Exercise	Stock options (right to buy)	200	$0.00	$0.00
Exercise	Common stock	200	$25.01	$5K
Sale	Common stock	200	$43.81	$9K

Holdings After Transaction: Stock options (right to buy) — 28,584 contracts (Direct); Common stock — 61,727 shares (Direct)

Footnotes (2)

1. F1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
2. F2. This option was originally granted on March 1, 2023 for the purchase of 44,000 shares of common stock. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AGIO report for its CMO?

On 10/30/2025, the CMO exercised 200 options at $25.01 and sold 200 shares at $43.81 under a Rule 10b5-1 plan.

How many AGIO shares did the insider hold after the transaction?

The reporting person held 61,727 shares of common stock directly after the reported trades.

How many AGIO stock options does the insider still hold and when do they expire?

She beneficially owned 28,584 options after the transaction, with an expiration date of 03/01/2033 and an exercise price of $25.01.

Was the AGIO share sale made under a Rule 10b5-1 plan?

Yes. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

What are the vesting terms of the AGIO option grant mentioned?

The option was granted on 03/01/2023 for 44,000 shares, vesting 25% on 03/01/2024 and the remaining 75% in 36 equal monthly installments thereafter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/03/2025 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gheuens Sarah

(Last) (First) (Middle)

88 SIDNEY STREET

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AGIOS PHARMACEUTICALS, INC. [ AGIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	10/30/2025		M		200	A	$25.01	61,927	D
Common stock	10/30/2025		S(1)		200	D	$43.81	61,727	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock options (right to buy)	$25.01	10/30/2025		M			200	(2)	03/01/2033	Common stock	200	$0	28,584	D

Explanation of Responses:

1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

2. This option was originally granted on March 1, 2023 for the purchase of 44,000 shares of common stock. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Remarks:

	/s/ William Cook, as attorney-in-fact for Sarah Gheuens	11/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.